Clinical Trials Directory

Trials / Unknown

UnknownNCT02532790

The Research of Standard Diagnosis and Treatment for HSPN With Mild Proteinuria in Children

The Research of Standard Diagnosis and Treatment for Henoch-Schonlein Purpura Nephritis With Mild Proteinuria in Children

Status
Unknown
Phase
Phase 2
Study type
Interventional
Enrollment
100 (estimated)
Sponsor
Nanjing Children's Hospital · Academic / Other
Sex
All
Age
2 Years – 16 Years
Healthy volunteers
Not accepted

Summary

This study is performed to evaluate the efficacy and safety of various measures in the treatment of HSPN with mild proteinuria in children.

Detailed description

Henoch-Schonlein purpura nephritis (HSPN) is one of the most common complications of Henoch-Schonlein purpura, and has become one of the main causes of chronic kidney disease in children. However, the diagnosis and treatment of HSPN is still based on the clinical experience, lacking of evidence-based support. This study is performed to explore the biological markers for early prediction of the prognosis and evaluate the efficacy and safety of various measures in the treatment of HSPN in children. The patients who are proved to get HSPN by renal biopsy will be randomized to receive either prednisone p.o. or angiotensin-converting enzyme inhibitor(ACEI) p.o. We will follow up them for about 2.5 years and compare the efficacy and safety of both measures by monitoring several indexes.

Conditions

Interventions

TypeNameDescription
DRUGPrednisone1.5mg/kg/d
DRUGACEI0.2-0.3mg/kg/d

Timeline

Start date
2015-08-01
Primary completion
2020-07-01
Completion
2020-07-01
First posted
2015-08-26
Last updated
2020-02-26

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT02532790. Inclusion in this directory is not an endorsement.